Log In

Company : 1abtik ag 
Monday, October 26, 2015 6:15PM IST (12:45PM GMT)
1abtik ag Founded to Fight Sepsis with Novel Antibody Therapeutics
Hünenberg, Switzerland

The 1abtik ag was recently founded with the sole focus to develop a game-changing antibody-based therapy for sepsis. 1abtik has now entered the financing phase for the drug development process ranging from the identification of lead compounds to running clinical studies including phase 2.


Sepsis is a disease with a confirmed very high unmet medical need that may affect any person. It often starts with unspectacular, mostly bacterial but also viral, fungal or parasite infections. However, it then seizes the entire body with a very high rate of mortality of up to 30% - 80%, depending on the severity. Close to 20mio cases of sepsis are assumed worldwide per year. The average population mortality rate related to this devastating inflammation is about 60-80 per 100'000. Moreover, up to 50% of the survivors suffer from the post-sepsis syndrome (PSS). World-wide, sepsis is one of the most expensive diseases requiring intensive care unit and emergency room settings.


Currently, there are no approved sepsis-specific drugs available.


1abtik now sets out to provide novel, potent antibody drugs required to lead such program to success. 1abtik is uniquely positioned for this purpose by planning to integrate unappreciated latest scientific data and disease target molecules with highest potency, tailor-made antibodies and in-depth know-how in the field. Past efforts to fight sepsis could neither profit from the recent scientific progress nor from the significant further development of high-end therapeutic antibodies.


For more information and details, please check www.1abtik.com and/or address fight.sepsis@1abtik.com




This communication contains certain forward-looking statements, relating to 1abtik's business, general discussions of strategy and plans or intentions of 1abtik. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the results of operations, financial condition, performance, or achievements, or industry results of 1abtik to be materially different from any strategy or plans or future results expressed or implied by such forward-looking statements.


+++++ Additional features:


Document: http://n.equitystory.com/c/fncls.ssp?u=IXNRCBNRGG


Document title: 1abtik ag


403113 26.10.2015



For News Release background on 1abtik ag click here
Media Contact Details
CONTACTS : 1abtik ag Titus Kretzschmar, PhD Founder and CEO titus.kretzschmar@1abtik.com
Submit your press release
Similar News

20/04/2018 11:00AM

Pfizer Lease Signed; USD 1.8B Construction Loan From Blackstone Secured; CanAm Set to Close on Initial Round of EB-5 Funds Raised for Tishman Speyer’s Spiral Project

CanAm Enterprises (CanAm) is pleased to report that its Spiral Project has achieved several of its milestones last week. Pfizer, the international pharmaceutical giant, signed a 20-year lease totaling approximately ...

No Image

18/04/2018 7:36PM

Boehringer Ingelheim to invest €65 million in avian vaccines

Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Porte-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian ...